Recommended Subtopics for Your Narrative Review

const {
  Document, Packer, Paragraph, TextRun, HeadingLevel,
  AlignmentType, UnderlineType, TableOfContents, StyleLevel,
  NumberFormat, Footer, PageNumber, convertInchesToTwip,
  BorderStyle, Table, TableRow, TableCell, WidthType, ShadingType,
  VerticalAlign
} = require('docx');
const fs = require('fs');

// ── helpers ─────────────────────────────────────────────────────────────────
const h1 = (text) => new Paragraph({
  text, heading: HeadingLevel.HEADING_1,
  spacing: { before: 360, after: 120 },
});
const h2 = (text) => new Paragraph({
  text, heading: HeadingLevel.HEADING_2,
  spacing: { before: 240, after: 80 },
});
const h3 = (text) => new Paragraph({
  text, heading: HeadingLevel.HEADING_3,
  spacing: { before: 200, after: 60 },
});
const body = (text, opts = {}) => new Paragraph({
  children: [new TextRun({ text, font: 'Times New Roman', size: 24, ...opts })],
  alignment: AlignmentType.JUSTIFIED,
  spacing: { before: 80, after: 80, line: 360 },
  indent: { firstLine: convertInchesToTwip(0.5) },
});
const bodyBold = (text) => body(text, { bold: true });
const blank = () => new Paragraph({ text: '' });

const cite = (text) => new Paragraph({
  children: [new TextRun({ text, font: 'Times New Roman', size: 20, italics: true, color: '444444' })],
  alignment: AlignmentType.LEFT,
  spacing: { before: 40, after: 40, line: 280 },
  indent: { left: convertInchesToTwip(0.3) },
});

// Build table helper
function makeTable(headers, rows, colWidths) {
  const headerRow = new TableRow({
    tableHeader: true,
    children: headers.map((h, i) => new TableCell({
      width: { size: colWidths[i], type: WidthType.PERCENTAGE },
      shading: { type: ShadingType.SOLID, color: '1F4E79', fill: '1F4E79' },
      verticalAlign: VerticalAlign.CENTER,
      children: [new Paragraph({
        children: [new TextRun({ text: h, bold: true, color: 'FFFFFF', size: 20, font: 'Calibri' })],
        alignment: AlignmentType.CENTER, spacing: { before: 60, after: 60 },
      })],
    })),
  });
  const dataRows = rows.map((row, ri) => new TableRow({
    children: row.map((cell, ci) => new TableCell({
      width: { size: colWidths[ci], type: WidthType.PERCENTAGE },
      shading: { type: ShadingType.SOLID, color: ri % 2 === 0 ? 'FFFFFF' : 'D6E4F0', fill: ri % 2 === 0 ? 'FFFFFF' : 'D6E4F0' },
      children: [new Paragraph({
        children: [new TextRun({ text: cell, size: 18, font: 'Calibri' })],
        alignment: AlignmentType.LEFT, spacing: { before: 40, after: 40 },
      })],
    })),
  }));
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [headerRow, ...dataRows],
    margins: { top: 60, bottom: 60, left: 100, right: 100 },
  });
}

// ── DOCUMENT CONTENT ─────────────────────────────────────────────────────────
const doc = new Document({
  styles: {
    paragraphStyles: [
      {
        id: 'Heading1', name: 'Heading 1', basedOn: 'Normal',
        run: { bold: true, size: 32, color: '1F4E79', font: 'Calibri' },
        paragraph: { spacing: { before: 400, after: 120 } },
      },
      {
        id: 'Heading2', name: 'Heading 2', basedOn: 'Normal',
        run: { bold: true, size: 26, color: '2E75B6', font: 'Calibri' },
        paragraph: { spacing: { before: 280, after: 80 } },
      },
      {
        id: 'Heading3', name: 'Heading 3', basedOn: 'Normal',
        run: { bold: true, italics: true, size: 24, color: '2E75B6', font: 'Calibri' },
        paragraph: { spacing: { before: 200, after: 60 } },
      },
    ],
  },
  sections: [{
    properties: {
      page: {
        margin: {
          top: convertInchesToTwip(1), bottom: convertInchesToTwip(1),
          left: convertInchesToTwip(1.25), right: convertInchesToTwip(1),
        },
      },
    },
    footers: {
      default: new Footer({
        children: [new Paragraph({
          children: [new TextRun({ children: [PageNumber.CURRENT], font: 'Calibri', size: 18 })],
          alignment: AlignmentType.CENTER,
        })],
      }),
    },
    children: [

      // ═══ TITLE PAGE ═══════════════════════════════════════════════════════
      new Paragraph({
        children: [new TextRun({ text: 'Targeting Distinct Immune Axes in Systemic Lupus Erythematosus:', bold: true, size: 36, font: 'Calibri', color: '1F4E79' })],
        alignment: AlignmentType.CENTER, spacing: { before: 1000, after: 120 },
      }),
      new Paragraph({
        children: [new TextRun({ text: 'A Comparative Narrative Review of Anifrolumab, Telitacicept, and Nipocalimab', bold: true, size: 32, font: 'Calibri', color: '1F4E79' })],
        alignment: AlignmentType.CENTER, spacing: { before: 0, after: 400 },
      }),
      new Paragraph({
        children: [new TextRun({ text: 'Narrative Review Article', size: 24, italics: true, font: 'Calibri', color: '555555' })],
        alignment: AlignmentType.CENTER, spacing: { before: 0, after: 600 },
      }),
      blank(), blank(), blank(),
      new Paragraph({
        children: [new TextRun({ text: 'Keywords: ', bold: true, size: 22, font: 'Calibri' }), new TextRun({ text: 'Systemic lupus erythematosus, Anifrolumab, Telitacicept, Nipocalimab, Biologics, Type I interferon, BAFF, APRIL, FcRn, Immune pathways, Precision medicine', size: 22, font: 'Calibri' })],
        alignment: AlignmentType.CENTER, spacing: { before: 0, after: 120 },
      }),

      // ═══ PAGE BREAK ═══════════════════════════════════════════════════════
      new Paragraph({ pageBreakBefore: true, text: '' }),

      // ═══ ABSTRACT ══════════════════════════════════════════════════════════
      h1('Abstract'),
      h2('Background'),
      body('Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by dysregulation of multiple immune pathways, including type I interferon (IFN) signaling, B-cell activation via B lymphocyte stimulator (BAFF) and a proliferation-inducing ligand (APRIL), and the persistence of pathogenic IgG autoantibodies. Despite advances in conventional immunosuppression, a substantial proportion of patients remain inadequately controlled, sustaining progressive organ damage and an unacceptably high mortality burden. Recent advances have led to the development of targeted biologics - anifrolumab, telitacicept, and nipocalimab - each acting on a distinct immune axis.'),
      h2('Objectives'),
      body('This narrative review comparatively evaluates the mechanisms of action, clinical trial evidence, efficacy, safety, and therapeutic positioning of anifrolumab, telitacicept, and nipocalimab in the management of SLE, framing them within the upstream-midstream-downstream model of SLE immunopathogenesis.'),
      h2('Methods'),
      body('A narrative review was conducted using data from peer-reviewed journals, clinical trial databases (ClinicalTrials.gov), and regulatory reports published up to July 2026. Sources included randomized controlled trials (RCTs), phase II/III trials, systematic reviews, meta-analyses, and authoritative reviews identified through PubMed and MEDLINE. As this review utilized only secondary published data, no ethical approval was required.'),
      h2('Results'),
      body('Anifrolumab, targeting the type I IFN receptor (IFNAR1), demonstrated sustained efficacy across the TULIP phase III program, with particular benefit in patients with high IFN gene signatures, and received FDA approval in 2021. Telitacicept, a dual BAFF/APRIL inhibitor, achieved SRI-4 response rates of 67.1-75.8% versus 32.7-33.9% for placebo in phase IIb and phase III trials, with a recent NEJM phase III (2025) confirming landmark efficacy. Network meta-analysis places telitacicept as the most efficacious biologic by SRI-4 response. Nipocalimab, an FcRn inhibitor, accelerates IgG catabolism across the board, directly reducing circulating pathogenic autoantibodies - a downstream mechanism distinct from both other agents.'),
      h2('Conclusion'),
      body('These three agents target different stages of SLE pathogenesis - upstream cytokine signaling, midstream B-cell activation, and downstream antibody persistence - and represent complementary rather than competing therapeutic strategies. Precision biomarker-guided patient selection, particularly IFN gene signature testing for anifrolumab and B-cell profiling for telitacicept, may optimize outcomes. Future head-to-head trials and combination therapy studies are needed to fully define their roles in individualized SLE management.'),

      // ═══ PAGE BREAK ═══════════════════════════════════════════════════════
      new Paragraph({ pageBreakBefore: true, text: '' }),

      // ═══ 1. INTRODUCTION ═════════════════════════════════════════════════
      h1('1. Introduction'),
      body('Systemic lupus erythematosus (SLE) is a paradigmatic systemic autoimmune disease that affects approximately 3.4 million people worldwide, with a striking female predominance of 9:1 [1]. The disease is characterized by immune-mediated injury across multiple organ systems - most prominently the skin, joints, kidneys, and central nervous system - and follows a relapsing-remitting course punctuated by potentially life-threatening flares [2]. Despite a 10-year survival exceeding 90% in resource-rich settings, mortality from SLE remains two to three times higher than that of the general population, principally from renal failure, cardiovascular disease, and infection [3].'),
      body('The immunopathological complexity of SLE poses a formidable therapeutic challenge. For decades, treatment relied almost exclusively on broad-spectrum immunosuppressants - hydroxychloroquine (HCQ), glucocorticoids, azathioprine, mycophenolate mofetil (MMF), and cyclophosphamide - agents associated with significant cumulative toxicity and incomplete disease control in a substantial subset of patients [1,2]. The era of targeted biologic therapy in SLE began with the approval of belimumab in 2011, a monoclonal antibody against BAFF, which, while efficacious, does not address the full range of pathogenic mechanisms at play [4].'),
      body('Three newly developed biologics - anifrolumab, telitacicept, and nipocalimab - each engage a fundamentally distinct immunological axis in SLE: type I interferon signaling, dual BAFF/APRIL-mediated B-cell survival, and neonatal Fc receptor (FcRn)-mediated IgG homeostasis, respectively. The conceptual framing of these agents as acting "upstream," "midstream," and "downstream" in the SLE pathogenic cascade provides a rational basis for understanding their individual efficacy profiles, safety considerations, and potential for complementary or sequential use.'),
      body('This narrative review examines the mechanistic foundations, pivotal clinical trial data, comparative efficacy, and safety profiles of these three agents, with the goal of informing their therapeutic positioning in modern SLE management. The implications of precision biomarker selection and the prospect of combination approaches are also discussed.'),

      // ═══ 2. IMMUNOPATHOGENESIS ════════════════════════════════════════════
      h1('2. Immunopathogenesis of SLE: The Three Targetable Axes'),
      body('SLE arises from a complex interplay of genetic predisposition, environmental triggers, and stochastic immune dysregulation, culminating in loss of self-tolerance and production of pathogenic autoantibodies [2]. The disease is underpinned by multiple immunoregulatory defects, and research over the past two decades has delineated at least three major axes that are both central to pathogenesis and amenable to pharmacological targeting.'),

      h2('2.1 Axis I: Type I Interferon Signaling'),
      body('The type I interferon (IFN) pathway occupies a pivotal upstream position in SLE immunopathogenesis. Plasmacytoid dendritic cells (pDCs) serve as the primary producers of IFN-alpha and IFN-beta in response to nucleic acid-containing immune complexes via toll-like receptors TLR7 and TLR9, as well as cytosolic sensors such as the cGAS-STING pathway [5]. This IFN-alpha/beta overproduction, in turn, activates downstream JAK-STAT signaling, driving the transcription of hundreds of IFN-stimulated genes (ISGs). The resulting transcriptomic profile - termed the IFN gene signature - is detectable in peripheral blood mononuclear cells and is present in 60-80% of patients with active SLE [6].'),
      body('The consequences of chronic IFN excess are far-reaching: IFN-alpha/beta promotes differentiation of monocytes into dendritic cells, activates autoreactive T and B lymphocytes, enhances antigen presentation, and facilitates the development of pathogenic anti-dsDNA antibodies [5]. Furthermore, IFN drives NET (neutrophil extracellular trap) formation, providing a continuing source of immunostimulatory self-DNA and thereby sustaining the inflammatory cycle. The strength of the IFN gene signature correlates with disease activity and the presence of renal and cutaneous involvement, establishing it as both a biomarker of disease state and a therapeutic target [6].'),

      h2('2.2 Axis II: BAFF/APRIL-Mediated B-Cell Survival'),
      body('B lymphocytes and their autoantibody-producing progeny, plasma cells, are central effectors in SLE. Two TNF superfamily cytokines - B-cell activating factor (BAFF, also known as BLyS) and a proliferation-inducing ligand (APRIL) - are essential for B-cell maturation, survival, and differentiation into long-lived plasma cells [7]. Elevated serum BAFF levels are consistently documented in SLE patients and correlate with disease activity, anti-dsDNA titers, and the risk of flares [8].'),
      body('BAFF signals principally through three receptors on B cells: BAFF-R, TACI, and BCMA. APRIL, while unable to bind BAFF-R, signals through TACI and BCMA. This dual signaling axis supports not only transitional and naive B-cell survival (primarily through BAFF/BAFF-R interactions) but also the long-term maintenance of autoantibody-secreting plasma cells (primarily through APRIL/TACI and APRIL/BCMA interactions) [8]. The distinction is clinically relevant: agents that block only BAFF (e.g., belimumab) may insufficiently suppress the plasma cell compartment that is driven by APRIL, whereas dual BAFF/APRIL blockade theoretically provides more complete B lineage suppression.'),
      body('Autoantibodies produced by these cells - including anti-dsDNA, anti-Sm, anti-Ro/SSA, and antiphospholipid antibodies - drive organ damage through immune complex deposition and complement activation in the kidneys, skin, and other target organs, forming the immunological bridge between this midstream axis and the downstream antibody compartment [1,2].'),

      h2('2.3 Axis III: FcRn-Mediated IgG Persistence'),
      body('The neonatal Fc receptor (FcRn) is a non-classical MHC class I molecule expressed on endosomal membranes of many cell types, including endothelial cells, epithelial cells, and professional antigen-presenting cells. Its canonical function is to rescue IgG from lysosomal degradation: following endocytosis of IgG, FcRn binds IgG in the acidic endosome and recycles it back to the cell surface, releasing it into the circulation at neutral pH and thereby extending its half-life to approximately 21 days [9]. Without FcRn recycling, IgG half-life would be reduced to approximately 2 days.'),
      body('In autoimmune diseases, this same mechanism that normally maintains protective antibody levels also perpetuates pathogenic autoantibodies. Pharmacological blockade of FcRn prevents IgG rescue from lysosomal degradation, accelerating the catabolism of all circulating IgG subclasses - including disease-driving autoantibodies - by 50-70% within weeks of treatment initiation [9,10]. This downstream mechanism operates independently of B-cell number or activation state, providing a complementary approach to upstream and midstream interventions. Nipocalimab, efgartigimod, and rozanolixizumab represent the most clinically advanced FcRn inhibitors, though only nipocalimab is specifically considered here in the context of SLE [11].'),

      blank(),
      // Summary table
      new Paragraph({ children: [new TextRun({ text: 'Table 1. The Three Targetable Immune Axes in SLE', bold: true, size: 22, font: 'Calibri' })], spacing: { before: 200, after: 80 } }),
      makeTable(
        ['Axis', 'Key Players', 'Position in Pathogenesis', 'Targeted Agent'],
        [
          ['Axis I: Type I IFN Signaling', 'pDCs, TLR7/9, IFNAR1, JAK-STAT, ISGs', 'Upstream - innate immune amplification', 'Anifrolumab'],
          ['Axis II: BAFF/APRIL-B Cell Survival', 'BAFF, APRIL, TACI, BCMA, BAFF-R; B cells and plasma cells', 'Midstream - adaptive B-cell autoimmunity', 'Telitacicept'],
          ['Axis III: FcRn-IgG Persistence', 'FcRn, IgG recycling endosome; all IgG subclasses', 'Downstream - autoantibody perpetuation', 'Nipocalimab'],
        ],
        [20, 28, 32, 20]
      ),

      // ═══ 3. ANIFROLUMAB ═══════════════════════════════════════════════════
      new Paragraph({ pageBreakBefore: true, text: '' }),
      h1('3. Anifrolumab'),

      h2('3.1 Mechanism of Action'),
      body('Anifrolumab is a fully human IgG1 monoclonal antibody that binds with high affinity to subunit 1 of the type I IFN receptor (IFNAR1), blocking signaling by all type I IFN subtypes (IFN-alpha, IFN-beta, IFN-omega) [6]. By occupying IFNAR1, anifrolumab prevents the receptor dimerization required for downstream JAK1 and TYK2 phosphorylation, thereby interrupting JAK-STAT1/STAT2 signaling and abrogating the transcription of IFN-stimulated genes. This broad type I IFN blockade suppresses the IFN gene signature within weeks of treatment initiation and reduces the IFN-driven activation of downstream adaptive immune cells [5,6].'),
      body('Unlike downstream targeting of individual cytokines, anifrolumab acts at a convergence point of innate immune activation, broadly dampening IFN-alpha/beta-driven inflammation regardless of the upstream trigger. This mechanism is particularly relevant given that three-quarters of SLE patients exhibit an elevated IFN gene signature, making this pathway a high-value therapeutic target. Importantly, anifrolumab does not deplete immune cells and does not broadly suppress IgG levels, preserving key humoral immune functions [6].'),

      h2('3.2 Key Clinical Trials'),
      body('The pivotal clinical development program for anifrolumab in SLE comprises the MUSE phase II trial and the TULIP-1 and TULIP-2 phase III trials, supplemented by a 3-year long-term extension (LTE) and a subsequent phase III subcutaneous (SC) formulation trial.'),
      body('The MUSE phase II trial (n=305) established proof of concept, demonstrating significantly higher BICLA response rates with anifrolumab 300 mg (34.3%) versus placebo (17.6%) at week 24, particularly in patients with a high IFN gene signature (36.0% vs. 10.5%), providing early pharmacodynamic confirmation of the mechanism [6].'),
      body('TULIP-1 (n=457) failed to meet its pre-specified primary endpoint of SRI-4 response, largely attributed to definitional issues with the composite endpoint and unusually high background therapy optimization in the placebo group. However, BICLA response - a more stringent outcome measure - favored anifrolumab (36.2% vs. 25.6%). TULIP-2 (n=362) used BICLA as the primary endpoint and met it decisively: 47.8% of anifrolumab 300 mg patients versus 31.5% of placebo patients achieved a BICLA response at week 52 (adjusted difference 16.3 percentage points, p=0.001) [6]. Secondary outcomes across both trials demonstrated significant reductions in skin disease (CLASI scores), oral glucocorticoid dose, and annualized flare rates.'),
      body('The placebo-controlled LTE study, extending to 3 years, represents the longest placebo-controlled trial in SLE to date. In this study, anifrolumab was associated with lower rates of serious adverse events (SAEs; EAIR 8.5 vs. 11.2 per 100 patient-years), reduced cumulative glucocorticoid exposure, and greater improvement in the SLE Disease Activity Index compared with placebo, with no new safety signals emerging over the extended observation period [12].'),
      body('A 2025 post-hoc analysis of the TULIP trials and LTE evaluated lupus low disease activity state (LLDAS) and DORIS remission - outcomes recognized as associated with reduced organ damage and mortality. At week 208, 36.9% of anifrolumab-treated patients were in LLDAS versus 17.1% with placebo (OR 2.7; 95% CI 1.3-5.5), and time to first LLDAS attainment significantly favored anifrolumab (HR 1.56; p=0.0024) [13]. A phase III SC formulation trial (2026) confirmed non-inferiority of subcutaneous versus intravenous dosing, expanding administration convenience [14].'),

      h2('3.3 Efficacy Summary'),
      body('Across the TULIP program, anifrolumab consistently demonstrated: (1) approximately 16 percentage-point improvement in BICLA response over placebo; (2) significantly greater reductions in skin disease as measured by CLASI; (3) steroid-sparing effect with approximately 50% oral glucocorticoid reduction in more patients than placebo; (4) reduced annualized flare rates; and (5) long-term LLDAS and remission attainability. The IFN gene signature has emerged as a predictive biomarker - patients with high IFN scores derive greater benefit, though even patients with low IFN scores showed numerical improvement [6,13].'),

      h2('3.4 Safety Profile'),
      body('The most clinically relevant safety signal with anifrolumab is an increased risk of herpes zoster (HZ) infections, occurring in approximately 7.2% of anifrolumab-treated patients versus 1.1% with placebo in the TULIP-2 trial - consistent with the known immunomodulatory role of type I IFNs in limiting varicella-zoster virus reactivation. The LTE data confirmed this association, with no increase in the severity or systemic spread of HZ infections, and guidelines recommend live attenuated or recombinant zoster vaccination prior to initiating treatment where possible [12]. Upper respiratory tract infections were modestly more frequent with anifrolumab. Rates of serious infections, malignancy, and major adverse cardiovascular events were comparable between groups and remained low through 3+ years [12]. COVID-19-related adverse events were numerically higher in the anifrolumab arm in the LTE, though no cases occurred in fully vaccinated individuals. The drug does not cause significant hypogammaglobulinemia or B-cell depletion.'),

      h2('3.5 Regulatory Status and Therapeutic Positioning'),
      body('Anifrolumab (brand name Saphnelo) received FDA approval in July 2021 and EMA approval in February 2023 for the treatment of moderate-to-severe SLE in adults receiving standard therapy, excluding severe active lupus nephritis and CNS lupus from the approved indication. The 2023 EULAR SLE management update recommends anifrolumab as an add-on therapy for patients with inadequate response to HCQ and immunosuppressants, particularly for those with moderate-to-severe cutaneous and musculoskeletal disease and for steroid sparing [3]. Based on subgroup data, the drug is most likely to benefit patients with a demonstrable IFN gene signature, a biomarker that is now commercially available.'),

      // ═══ 4. TELITACICEPT ══════════════════════════════════════════════════
      new Paragraph({ pageBreakBefore: true, text: '' }),
      h1('4. Telitacicept'),

      h2('4.1 Mechanism of Action'),
      body('Telitacicept (RC18) is a recombinant fusion protein consisting of the extracellular domain of TACI (transmembrane activator and CAML interactor) fused to the Fc region of human IgG1. TACI is a receptor shared by both BAFF and APRIL; the telitacicept fusion protein therefore acts as a soluble decoy receptor, simultaneously sequestering both BAFF and APRIL and preventing their binding to cognate receptors on B cells and plasma cells [7,8].'),
      body('This dual inhibition is the defining mechanistic advantage over belimumab, which selectively targets BAFF alone. By blocking APRIL in addition to BAFF, telitacicept suppresses not only B-cell maturation and survival (mediated predominantly through BAFF/BAFF-R signaling) but also the survival and antibody production of long-lived bone marrow plasma cells (mediated through APRIL/BCMA and APRIL/TACI signaling). This broader suppression of the entire B lineage - from transitional B cells through plasma cells - is hypothesized to account for telitacicept\'s greater clinical efficacy compared to belimumab in indirect comparisons [7,8,15].'),
      body('Treatment with telitacicept results in significant reductions in circulating B cells, plasma cells, serum IgG, IgA, and IgM levels, normalization of anti-dsDNA titers, and restoration of complement levels, reflecting broad immune modulation across the B-cell axis [7,8].'),

      h2('4.2 Key Clinical Trials'),
      body('The clinical development of telitacicept in SLE has proceeded through a well-powered phase IIb trial and a landmark phase III trial published in the New England Journal of Medicine in 2025.'),
      body('The phase IIb trial (Wu et al., Ann Rheum Dis 2024) enrolled 249 patients with active SLE at 29 Chinese centers in a 48-week, randomized, double-blind, placebo-controlled design. Patients were randomized 1:1:1:1 to receive subcutaneous telitacicept 80 mg, 160 mg, 240 mg, or placebo once weekly in addition to standard therapy. The primary endpoint of SRI-4 response at week 48 was achieved in 71.0%, 68.3%, and 75.8% of the 80 mg, 160 mg, and 240 mg groups respectively, versus 33.9% with placebo (all p<0.001). Significant dose-dependent improvements were observed in SLEDAI scores, anti-dsDNA titers, and complement levels, with a glucocorticoid-sparing effect in the highest dose group [7].'),
      body('The phase III trial (van Vollenhoven et al., NEJM 2025; NCT04082416) was a 52-week, double-blind, placebo-controlled study that randomized 335 patients with active SLE (SELENA-SLEDAI score ≥8) 1:1 to telitacicept 160 mg subcutaneously once weekly or placebo, added to standard therapy. The primary endpoint - modified SRI-4 response at week 52 - was achieved by 67.1% of telitacicept-treated patients versus 32.7% with placebo (adjusted difference 34.5 percentage points; 95% CI 24.3-44.7; p<0.001). Secondary outcomes including SELENA-SLEDAI reduction, physician global assessment, and time to first flare all significantly favored telitacicept [8]. These phase III findings represent a substantial treatment effect, among the largest in any SLE biologic trial to date.'),

      h2('4.3 Efficacy Summary'),
      body('Across the phase IIb and phase III programs, telitacicept demonstrated: (1) SRI-4 response rates approximately 34-42 percentage points higher than placebo; (2) significant reductions in anti-dsDNA antibody levels and restoration of complement C3/C4; (3) reductions in glucocorticoid requirements; (4) consistent efficacy across organ domains including renal and cutaneous manifestations. A 2025 network meta-analysis (Ding et al., Clin Rev Allergy Immunol) directly comparing biologics for SLE across 29 RCTs and 13,712 patients found telitacicept to demonstrate the greatest improvement in SRI-4 response among all biologics (OR 5.2; 95% CI 1.4-20.0 vs. standard therapy) [16].'),
      body('A systematic review and meta-analysis published in Scientific Reports (2025) compared telitacicept with belimumab using indirect comparisons across 11 RCTs (4,303 participants) and found telitacicept superior to belimumab in SRI-4 response (RR 2.03; 95% CI 1.65-2.49; p<0.0001) and SRI-7 response (RR 3.61; 95% CI 1.57-8.29; p=0.002), without a significant difference in adverse events - supporting the hypothesis that dual BAFF/APRIL blockade confers an advantage over BAFF-only inhibition [15].'),

      h2('4.4 Safety Profile'),
      body('In the phase III trial, adverse events considered related to treatment were more common with telitacicept than placebo (74.9% vs. 50.0%). The most frequent treatment-related adverse events with telitacicept included upper respiratory tract infection (31.7% vs. 19.0%), reduced serum IgG (15.6% vs. 1.2%), reduced serum IgM (15.0% vs. 0.6%), and injection-site reactions (12.6% vs. 0.6%) [8]. Serious adverse events were not significantly different between groups. The immunoglobulin reduction, while consistent with the mechanism of suppressing plasma cells, raises considerations about infection susceptibility with long-term use. No cases of progressive multifocal leukoencephalopathy (PML) or opportunistic infections were reported. The overall safety profile was considered acceptable given the magnitude of the efficacy signal.'),

      h2('4.5 Regulatory Status and Therapeutic Positioning'),
      body('Telitacicept received approval by China\'s National Medical Products Administration (NMPA) in March 2021 for active SLE, marking a first-in-class dual BAFF/APRIL inhibitor. The landmark NEJM phase III data (2025) serve as the pivotal trial anticipated to support regulatory applications in the United States and European Union. If approved globally, telitacicept is expected to offer an alternative - and potentially superior - option to belimumab for patients with active SLE requiring B-cell-targeted therapy, particularly those with high disease activity, elevated anti-dsDNA titers, or complement consumption not adequately controlled by BAFF-only inhibition.'),

      // ═══ 5. NIPOCALIMAB ════════════════════════════════════════════════════
      new Paragraph({ pageBreakBefore: true, text: '' }),
      h1('5. Nipocalimab'),

      h2('5.1 Mechanism of Action'),
      body('Nipocalimab (M281) is a fully human, aglycosylated IgG1 monoclonal antibody that binds to the neonatal Fc receptor (FcRn) with high affinity at both neutral and acidic pH - a key feature that distinguishes it from some other FcRn inhibitors that bind only at acidic endosomal pH. The crystal structure of the nipocalimab Fab/FcRn complex reveals binding to a unique epitope on the IgG-binding site of FcRn, conferring pH-independent high affinity and resulting in sustained FcRn occupancy and dose-proportional IgG reduction [17].'),
      body('Critically, nipocalimab is aglycosylated - the Fc region has been engineered to lack N-linked glycosylation at Asn297 - meaning it cannot bind Fc gamma receptors (FcgRI, FcgRIIa, FcgRIIIa) or C1q. This prevents complement activation and Fc-mediated effector functions (ADCC, ADCP), eliminating risks of cytokine release or immune cell depletion associated with glycosylated IgG antibodies [17]. The drug therefore selectively reduces IgG levels without broadly depleting immune cells or altering innate immune function.'),
      body('By blocking FcRn-mediated IgG rescue, nipocalimab accelerates the lysosomal degradation of all internalized IgG - reducing circulating total IgG and, critically, pathogenic IgG autoantibodies (including anti-dsDNA, antiphospholipid antibodies, anti-Ro/SSA) by approximately 50-70% within 2-4 weeks [9,17]. This broad reduction in IgG is class-wide and not specific to any autoantibody subset, which is both a strength (applicable regardless of which autoantibody predominates) and a limitation (concurrent reduction of protective IgG may impair vaccine responses and infection defense).'),

      h2('5.2 Preclinical and Clinical Evidence'),
      body('Nipocalimab\'s mechanism has been extensively validated across multiple IgG-mediated autoimmune and alloimmune conditions. In generalized myasthenia gravis (MG), randomized trials demonstrated significant reductions in total IgG and anti-AChR antibodies alongside clinical improvement in myasthenic symptoms. In fetal and neonatal alloimmune thrombocytopenia (FNAIT) and hemolytic disease of the fetus and newborn (HDFN), nipocalimab reduced pathogenic alloantibodies and improved fetal outcomes. These proof-of-concept datasets establish FcRn inhibition as a validated mechanism for reducing pathogenic IgG in a clinical setting [11].'),
      body('In the SLE context, the mechanistic rationale is compelling: SLE pathogenesis is fundamentally driven by IgG autoantibodies (anti-dsDNA, anti-Sm, antiphospholipid antibodies) that deposit in target organs and activate complement and Fc receptors to cause inflammation and tissue damage [1,2]. Reducing the circulating burden of these antibodies downstream of their production should reduce the inflammatory stimulus independent of whether B-cell activation has been adequately suppressed. In IgG-mediated autoimmune rheumatic diseases broadly, a 2025 review confirmed that FcRn inhibition "accelerates IgG catabolism and potentially dampens downstream inflammatory circuits by reducing immune-complex-mediated activation" [10].'),
      body('Post-hoc analyses of three randomized placebo-controlled nipocalimab trials (Yu et al., Hum Vaccin Immunother 2026) confirmed that nipocalimab significantly reduced IgG responses to vaccinations and blunted responses to new viral infections - a safety-relevant finding that requires attention to vaccination scheduling and infection surveillance during treatment [18]. SLE-specific phase III trial results for nipocalimab were not yet published as of the date of this review; ongoing clinical trials (NCT) are investigating nipocalimab in SLE and lupus nephritis.'),

      h2('5.3 Efficacy Potential in SLE'),
      body('Although SLE-specific RCT data for nipocalimab remain in active clinical development, extrapolation from its validated mechanism and related disease models supports several potential advantages. First, as a downstream agent, nipocalimab can reduce autoantibody levels rapidly - within days to weeks - making it conceptually suitable for acute, high-activity disease or as an add-on to agents that require weeks to months to suppress B-cell activation [9,17]. Second, its broad IgG-lowering effect is mechanism-agnostic with respect to autoantibody specificity, making it applicable to the heterogeneous autoantibody repertoire of SLE patients. Third, in patients with antiphospholipid syndrome - a common SLE comorbidity driven by IgG antiphospholipid antibodies - nipocalimab may directly reduce the thrombotic and obstetric risk by lowering circulating antiphospholipid antibody titers, a hypothesis under active investigation.'),

      h2('5.4 Safety Profile'),
      body('The central safety concern with nipocalimab, as with all FcRn inhibitors, is the class-wide reduction in total IgG, which necessarily includes protective antibody titers against pathogens and prior vaccinations. As demonstrated in the post-hoc analysis by Yu et al. (2026), nipocalimab reduced responses to vaccination during active treatment, though these responses were partially recoverable after drug discontinuation [18]. Baseline and monitoring of IgG levels is therefore essential. A review published in Inflammation Research (2026) identified key practical considerations for FcRn inhibitors: (1) a threshold IgG level below which infection risk rises substantially; (2) the importance of completing vaccinations before treatment initiation; and (3) the potential for dose modification or temporary discontinuation to preserve IgG levels during high-infection-risk periods [10]. Unlike telitacicept, nipocalimab does not directly suppress B-cell numbers or broadly suppress IgA/IgM, and it does not increase herpes zoster risk (unlike anifrolumab). The aglycosylated structure eliminates infusion reaction and ADCC-related risks.'),

      h2('5.5 Regulatory Status and Therapeutic Positioning'),
      body('Nipocalimab has received FDA approval for generalized myasthenia gravis (April 2024) and for prevention of severe HDFN (May 2024), establishing its regulatory standing. The SLE indication remains investigational as of mid-2026, pending phase III trial completion. Its therapeutic niche in SLE is anticipated to be in patients with predominantly antibody-driven manifestations - particularly those with high anti-dsDNA titers, active lupus nephritis with heavy proteinuria, or concomitant antiphospholipid syndrome - and potentially as a rapid-acting bridge while upstream immunosuppressants take effect.'),

      // ═══ 6. COMPARATIVE ANALYSIS ══════════════════════════════════════════
      new Paragraph({ pageBreakBefore: true, text: '' }),
      h1('6. Comparative Analysis'),

      h2('6.1 Mechanisms: Upstream, Midstream, and Downstream'),
      body('The three biologics reviewed target non-overlapping steps in the SLE immunopathogenic cascade. Anifrolumab acts furthest upstream, interrupting IFN-alpha/beta signaling before it can activate the adaptive immune system. Telitacicept operates midstream, at the level of B-cell and plasma cell survival, preventing the generation and maintenance of autoantibody-producing cells. Nipocalimab acts most downstream, directly reducing the burden of circulating IgG autoantibodies after they have been produced. This sequential positioning means the three agents are fundamentally complementary rather than simply competing alternatives: their combination could theoretically suppress disease at all three levels simultaneously, though this hypothesis awaits clinical validation.'),
      body('Each mechanism also carries organ-specific implications. The type I IFN axis has a particularly strong role in cutaneous and mucosal manifestations, consistent with anifrolumab\'s notable efficacy in skin disease. The BAFF/APRIL axis is most critical for systemic B-cell-driven disease with active serology (elevated anti-dsDNA, hypocomplementemia), consistent with telitacicept\'s pronounced effects on these biomarkers. The FcRn/IgG axis is relevant wherever pathogenic antibodies are the proximate driver of tissue injury - making nipocalimab most relevant in nephritis, antiphospholipid syndrome, and other antibody-deposition-mediated phenotypes.'),

      h2('6.2 Efficacy Comparison'),
      body('Direct head-to-head trial comparisons between the three agents do not exist; cross-trial efficacy comparisons are therefore inherently limited by differences in patient populations, background therapy, trial endpoints, and geographic enrollment. With these caveats, the 2025 network meta-analysis by Ding et al. (29 RCTs, 13,712 patients) provides the most rigorous available indirect comparison and is summarized in Table 2 below [16].'),
      blank(),
      new Paragraph({ children: [new TextRun({ text: 'Table 2. Comparative Efficacy of Selected Biologics for SLE (Network Meta-Analysis, Ding et al. 2025)', bold: true, size: 22, font: 'Calibri' })], spacing: { before: 160, after: 80 } }),
      makeTable(
        ['Agent', 'SRI-4 OR vs. Standard Therapy', 'BICLA OR vs. Standard Therapy', 'Key Trial'],
        [
          ['Telitacicept 160 mg', 'OR 5.2 (95% CI 1.4-20.0)*', 'Data limited', 'NEJM Phase III 2025'],
          ['Anifrolumab 300 mg', 'Numerically favorable', 'OR 1.6 (95% CI 1.3-2.0)', 'TULIP-2 Phase III'],
          ['Belimumab 10 mg/kg IV', 'OR ~1.5-2.0 (meta-analysis)', 'OR ~1.3-1.5', 'BLISS-52 / BLISS-76'],
          ['Deucravacitinib (TYK2i)', 'Favorable', 'OR 1.6 (95% CI 1.0-2.5)', 'Phase II SLE'],
          ['Nipocalimab', 'Phase III pending in SLE', 'Phase III pending in SLE', 'Ongoing trials'],
        ],
        [20, 22, 22, 36]
      ),
      blank(),
      body('*Wide confidence interval reflects limited phase III data at time of analysis; updated with NEJM 2025 trial data in Qian et al. meta-analysis (RR 2.03 telitacicept vs. belimumab for SRI-4; p<0.0001) [15].'),
      body('The meta-analytic data position telitacicept as having the largest effect size for SRI-4 response, likely reflecting the breadth of its B-cell-targeting mechanism. Anifrolumab demonstrates the most consistent signal in BICLA-defined outcomes and skin-specific endpoints. These differences likely reflect, in part, the different patient populations studied rather than true intrinsic efficacy differences, underscoring the need for biomarker-guided patient selection.'),

      h2('6.3 Biomarker-Guided Patient Selection'),
      body('One of the most clinically actionable lessons from the biologic era in SLE is that patient stratification by disease phenotype and biomarker profile is likely to maximize therapeutic benefit. For anifrolumab, the IFN gene signature score - measured from peripheral blood mononuclear cells - serves as the primary predictive biomarker: patients with a high IFN signature (approximately 75-80% of SLE patients) derived significantly greater BICLA responses than those with low IFN signatures in pooled analyses, establishing IFN gene signature testing as a clinically useful tool prior to initiation [6,16].'),
      body('For telitacicept, the most likely responders are patients with evidence of active B-cell-driven disease: elevated anti-dsDNA titers, reduced complement levels, and high disease activity despite HCQ. This phenotype overlaps substantially with the population studied in the phase IIb and phase III trials (predominantly Chinese populations with active SLE), and the serological normalization observed in these trials supports BAFF/APRIL-driven B-cell activation as the predominant pathogenic driver in this subset [7,8].'),
      body('For nipocalimab, the most rational targets are patients in whom pathogenic IgG autoantibodies are the primary drivers of damage - notably those with lupus nephritis classes III-IV (immune complex-mediated), antiphospholipid syndrome with ongoing thrombotic risk, or neonatal lupus concerns (maternal anti-Ro/SSA antibodies in pregnancy). The broad-spectrum IgG reduction of nipocalimab makes it theoretically applicable across autoantibody-diverse SLE, but clinical trial confirmation is needed.'),

      h2('6.4 Safety Comparison'),
      body('The three agents carry distinct mechanism-driven safety profiles that require individualized monitoring (Table 3). Anifrolumab\'s primary safety concern is herpes zoster reactivation, consequent to IFN-alpha\'s role in antiviral immunity. This risk is manageable through pre-treatment vaccination (recombinant zoster vaccine preferred) and antiviral prophylaxis in high-risk patients. The LTE data over 3+ years provide reassurance that serious infections, malignancy, and cardiovascular events are not significantly elevated [12].'),
      body('Telitacicept\'s suppression of BAFF/APRIL leads to reductions in IgG, IgA, and IgM - a consequence of plasma cell suppression. Upper respiratory tract infections were the most common adverse event in the phase III trial. The magnitude of immunoglobulin reduction is expected to be intermediate between belimumab (modest) and nipocalimab (substantial), as it targets plasma cell generation rather than existing IgG catabolism. Long-term immunoglobulin monitoring is appropriate [8,15].'),
      body('Nipocalimab produces the most pronounced IgG reduction of the three agents (50-70% reduction in total IgG), raising the most significant infection and vaccine-response concern. Importantly, this is a class-wide IgG effect that does not spare any IgG subclass, including anti-infective antibodies. Unlike anifrolumab and telitacicept, nipocalimab does not increase herpes zoster risk and does not affect B-cell or T-cell numbers [9,11,18].'),
      blank(),
      new Paragraph({ children: [new TextRun({ text: 'Table 3. Comparative Safety Profiles', bold: true, size: 22, font: 'Calibri' })], spacing: { before: 160, after: 80 } }),
      makeTable(
        ['Safety Domain', 'Anifrolumab', 'Telitacicept', 'Nipocalimab'],
        [
          ['Herpes Zoster', 'Increased (7.2% vs 1.1%)', 'Not elevated above SLE baseline', 'Not elevated'],
          ['Infections (serious)', 'Comparable to placebo (LTE)', 'URTI more frequent (31.7% vs 19.0%)', 'IgG-dependent risk expected; monitoring required'],
          ['Immunoglobulin levels', 'Not significantly affected', 'IgG/IgM/IgA reduced (15-16% incidence of low Ig)', 'Total IgG reduced ~50-70%'],
          ['Vaccine response', 'Preserved', 'Potentially impaired (plasma cell suppression)', 'Significantly reduced during treatment'],
          ['B-cell depletion', 'None', 'B-cell reduction (BAFF/APRIL dependent survival)', 'None'],
          ['Injection-site reactions', 'Infusion reactions (IV); SC well tolerated', '12.6% injection site reactions', 'Expected for IV/SC biologic administration'],
          ['Malignancy', 'Comparable to placebo (LTE data)', 'Data limited to 52 weeks', 'Not established in SLE'],
        ],
        [24, 25, 26, 25]
      ),

      h2('6.5 Therapeutic Positioning and Sequencing'),
      body('In the absence of head-to-head trials, therapeutic positioning must be guided by disease phenotype, organ involvement, biomarker profile, and prior treatment history. A practical framework is proposed as follows:'),
      body('For patients with moderate-to-severe SLE with active skin disease and/or musculoskeletal involvement, a positive IFN gene signature, and inadequate response to HCQ and low-dose corticosteroids, anifrolumab represents the biologically rational first biologic choice. Its strong efficacy in cutaneous endpoints and its established long-term safety profile make it well-suited for this phenotype, and it received guideline endorsement in the 2023 EULAR recommendations.'),
      body('For patients with serologically active SLE (high anti-dsDNA, low complement, moderate-to-severe SLEDAI) who have not been controlled by HCQ and who require B-cell targeted therapy, telitacicept offers a compelling alternative to belimumab with a potentially superior efficacy profile based on current indirect comparative evidence. Patients with lupus nephritis that has responded insufficiently to MMF or azathioprine may also benefit, given the BAFF/APRIL contribution to plasma cell-driven glomerular IgG deposition.'),
      body('For patients with refractory, antibody-driven disease - particularly those with persistently elevated anti-dsDNA titers, active lupus nephritis resistant to conventional induction, or concomitant antiphospholipid syndrome - nipocalimab holds promise as a downstream rescue strategy or combination agent. Its rapid IgG-lowering onset also makes it conceptually attractive as a bridge intervention while slower-acting immunosuppressants take effect, provided IgG level monitoring is maintained.'),

      // ═══ 7. FUTURE DIRECTIONS ════════════════════════════════════════════
      new Paragraph({ pageBreakBefore: true, text: '' }),
      h1('7. Unresolved Questions and Future Directions'),
      body('Despite the substantial progress represented by these three agents, several important questions remain unanswered and define the research agenda for the next decade.'),
      body('Long-term durability and safety data beyond 1-2 years are available only for anifrolumab (3-year LTE). For telitacicept and nipocalimab, long-term outcomes - including sustained remission, organ damage accrual, cardiovascular risk modification, and cumulative infection burden - are not yet established in SLE. Extension studies from current phase III programs will be essential.'),
      body('The comparative and combination potential of these agents represents perhaps the most exciting frontier. Since the three drugs target non-overlapping axes, combination therapy - for example, anifrolumab plus telitacicept (targeting IFN plus B-cell survival simultaneously) or nipocalimab plus telitacicept (suppressing antibody production and accelerating degradation) - is mechanistically rational. However, such combinations carry compounded infection risks, particularly hypogammaglobulinemia, and require carefully designed safety-first phase II trials before broader adoption. The Bayesian network meta-analysis by Ding et al. (2025) explicitly called for head-to-head trials to validate the indirect comparisons and to evaluate combination strategies [16].'),
      body('Biomarker validation and standardization is another critical gap. While the IFN gene signature is commercially available for clinical use (e.g., the Ampel IFN gene signature test), BAFF/APRIL serum levels and B-cell subset profiling are not yet standardized as routine clinical tests to guide telitacicept initiation. Nipocalimab lacks any identified predictive biomarker beyond the general category of "IgG-mediated disease." Precision medicine in SLE requires prospective validation of these stratification tools in diverse populations.'),
      body('Special populations deserve dedicated attention. Pregnancy is a high-risk setting in SLE, and the use of these agents in pregnant patients is not established for any of the three. Neonatal lupus, driven by maternal anti-Ro/SSA IgG antibodies crossing the placenta, presents a theoretically tractable indication for nipocalimab - FcRn is the receptor responsible for maternal IgG transfer to the fetus, and nipocalimab\'s IgG-lowering effect could potentially reduce fetal antibody burden - and trials in this specific context are ongoing. Pediatric SLE remains an important and underserved area across all three agents.'),
      body('Finally, global access and health economics pose pragmatic challenges. All three agents are high-cost biologics; telitacicept has an advantage in that it is currently available in China and is expected to have manufacturing cost advantages as a fusion protein. The 2023 EULAR guidelines acknowledged that access to expensive biologics remains highly variable across world regions, and this disparity is expected to persist with the newer agents unless pricing reform or biosimilar competition occurs [3].'),
      body('Emerging next-generation approaches - including CAR-T cell therapy targeting CD19/CD38 (with early remarkable results in refractory SLE), obinutuzumab (a next-generation anti-CD20 with enhanced B-cell depletion), and deucravacitinib (a TYK2 inhibitor active in SLE) - add further depth to the therapeutic landscape, though they fall outside the scope of this review.'),

      // ═══ 8. CONCLUSION ════════════════════════════════════════════════════
      h1('8. Conclusion'),
      body('Anifrolumab, telitacicept, and nipocalimab represent a conceptual and therapeutic advance in SLE management by targeting distinct, mechanistically non-redundant axes of the disease\'s immunopathogenesis. Anifrolumab interrupts upstream type I IFN amplification and has established its efficacy and long-term safety through an extensive clinical trial program leading to global regulatory approval. Telitacicept, with its dual BAFF/APRIL blockade, offers broader B-lineage suppression than existing anti-BAFF therapies and has demonstrated the largest SRI-4 effect sizes of any SLE biologic in current trial data, with global approvals anticipated following its NEJM phase III publication. Nipocalimab, acting downstream via FcRn inhibition to reduce circulating pathogenic IgG, offers a mechanism-agnostic approach to autoantibody burden reduction that complements both upstream and midstream interventions, with SLE-specific trial results awaited.'),
      body('The upstream-midstream-downstream framework presented here provides clinicians with a practical mental model for matching biological mechanisms to individual patient profiles. Moving forward, precision medicine approaches leveraging IFN gene signatures, BAFF/APRIL biomarkers, and autoantibody profiling will be essential to maximize the benefit of these targeted therapies. The development of head-to-head and combination trial designs, along with strategies to ensure equitable global access, represents the most important priority for the next phase of SLE biologic therapy research.'),

      // ═══ REFERENCES ════════════════════════════════════════════════════════
      new Paragraph({ pageBreakBefore: true, text: '' }),
      h1('References'),
      cite('1. Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet. 2024;403(10441):2326-2338. doi:10.1016/S0140-6736(24)00398-2. PMID: 38642569.'),
      cite('2. Siegel CH, Sammaritano LR. Systemic Lupus Erythematosus: A Review. JAMA. 2024;331(17):1480-1491. doi:10.1001/jama.2024.2315. PMID: 38587826.'),
      cite('3. Kostopoulou M, Mukhtyar CB, Bertsias G, et al. Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations. Ann Rheum Dis. 2024;83(10):1489-1501. doi:10.1136/ard-2024-225815. PMID: 38777375.'),
      cite('4. Kato H, Kahlenberg JM. Emerging biologic therapies for systemic lupus erythematosus. Curr Opin Rheumatol. 2024;36(3):143-151. doi:10.1097/BOR.0000000000001003. PMID: 38299618.'),
      cite('5. Baker T, Sharifian H, Newcombe PJ, et al. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials. Ann Rheum Dis. 2024;83(7):876-887. doi:10.1136/ard-2023-225204. PMID: 38569851.'),
      cite('6. Morand EF, van Vollenhoven R, Furie RA, et al. LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials. Ann Rheum Dis. 2025;84(5):623-633. doi:10.1016/j.ard.2025.01.016. PMID: 39948001.'),
      cite('7. Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(3):338-345. doi:10.1136/ard-2023-224854. PMID: 38129117.'),
      cite('8. van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, et al. A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus. N Engl J Med. 2025;393(16):1543-1553. doi:10.1056/NEJMoa2414719. PMID: 41092329.'),
      cite('9. Seth NP, Xu R, DuPrie M, et al. Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties. MAbs. 2025;17(1):2461191. doi:10.1080/19420862.2025.2461191. PMID: 39936406.'),
      cite('10. Liang P, Cai S, Sun W, Dong L. Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases. Inflamm Res. 2026;75(1):1-15. doi:10.1007/s00011-026-02279-6. PMID: 42257855.'),
      cite('11. Yang CW, Xia T, Tan Q, et al. From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases. Front Immunol. 2025;16:1656937. doi:10.3389/fimmu.2025.1656937. PMID: 41112287.'),
      cite('12. Kalunian KC, Furie R, Morand EF, et al. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis Rheumatol. 2023;75(2):253-265. doi:10.1002/art.42392. PMID: 36369793.'),
      cite('13. Morand EF, van Vollenhoven R, Furie RA, et al. LLDAS and remission attainment with anifrolumab: TULIP and LTE post hoc analysis. Ann Rheum Dis. 2025;84:623-633. PMID: 39948001.'),
      cite('14. Manzi S, Bruce IN, Morand EF, et al. Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study. Arthritis Rheumatol. 2026;78(6):741-751. PMID: 41466456.'),
      cite('15. Qian J, Lv X, Hu Y, et al. Effects of telitacicept and belimumab on systemic lupus erythematosus: a systematic review and meta-analysis. Sci Rep. 2025;15(1):48231. doi:10.1038/s41598-025-29929-9. PMID: 41310387.'),
      cite('16. Ding Z, Zhang H, Huang F, et al. Efficacy and Safety of Biologics for Systemic Lupus Erythematosus (SLE): A Systematic Review and Network Meta-Analysis. Clin Rev Allergy Immunol. 2025. doi:10.1007/s12016-025-09082-x. PMID: 40699272.'),
      cite('17. Seth NP, Xu R, DuPrie M, et al. Nipocalimab, an immunoselective FcRn blocker. MAbs. 2025;17(1):2461191. PMID: 39936406.'),
      cite('18. Yu F, Myshkin E, Nguyen B, et al. Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases. Hum Vaccin Immunother. 2026;22(1):2501834. PMID: 42084498.'),
    ],
  }],
});

Packer.toBuffer(doc).then((buffer) => {
  fs.writeFileSync('/tmp/workspace/sle-review/SLE_Narrative_Review.docx', buffer);
  console.log('Document written successfully.');
});